This work evaluated a serial blood sampling procedure to enhance the sensitivity of duplex 24 real time PCR (qPCR) for baseline detection and quantification of parasitic loads and post-25 treatment identification of failure in the context of clinical trials for treatment of chronic 26 Chagas disease, namely DNDi-CH-E1224-001 (NCT01489228) and MSF-DNDi PCR 27 sampling optimization study (NCT01678599). Patients from Cochabamba (N= 294), Tarija 28
For quantification purposes, standard curves were plotted with 1/10 serial dilutions of total 150 DNA obtained from a GEB seronegative sample spiked with 10 5 par. eq./mL LL014-1-R1 Cl1 In this trial, qPCR was firstly assayed in duplicate from each S1 and S2 DNA extract. When 194 both replicates gave non-detectable qPCR results from one of these DNA extracts, a third qPCR replicate was analyzed from the corresponding sample. When the third replicate was 196 included, qPCR positivity increased from 54.8 to 60.5% (for S1) and from 53.6 to 59.2% (for 197 S2) in samples collected from the Cochabamba cohort, and from 59.5 to 63.4% (S1) and from 198 55.3 to 60.7% (S2) in those collected from the Tarija cohort ( 
Analysis of serial blood samples 201
In the DNDi-CH-E1224-001 trial, the comparison of qPCR positivity obtained after testing 202 individual S1 or S2 samples did not give significant differences (Table 1, When S1 and S2 gave non-detectable qPCR results, a third sample, named S3 was taken 208 seven days later. The analysis of PCR positivity obtained using three serial samples 209 (S1+S2+S3) compared to that obtained from individual samples demonstrated higher 76.6%, p< 0.001; E1224 SD, 84.4%, p< 0.001; E1224 HD, 56.1%, p< 0.01), whereas in The number of patients in the placebo group of the DNDi-CH-E1224-001 trial with 278 quantifiable qPCRs results ranged between 14-16 during follow-up; except at 4 months when, 279 as at baseline, nine patients rendered quantifiable qPCR results ( Table 3) . Out of nine patients 280 enrolled in the placebo group of DNDi-CH-E1224-001 who showed quantifiable parasitic 281 loads at baseline (Table 3) in refractory patients with quantifiable parasitic loads (Fig 2A, p> 0 .05).
290
Patients treated with E1224 showed non-quantifiable parasitic loads at the end of treatment, 291 but this increased later on; indeed, 12 cases reached quantifiable loads for E1224 low dose 292 (LD) and short dose (SD) regimes and six in E1224 high dose (HD) regime at the end of follow-up; whereas in BZN treated groups only one sample gave parasitic loads >1.53 294 par.eq/mL during follow-up (Table 3) . In the DNDi-CH-E1224-001 trial, the multi-sampling strategy (S1+S2+S3) increased 306 detection of treatment failure at the end of follow-up by up to 91.7% for E1224 LD (Fig 3B, S1-3: samples 1-3; qPCR1-3: qPCR replicates 1-3; CBBA: Cochabamba; N: number of samples; IQR: interquartile range; par. eq./mL: parasite 510 equivalents in 1 mL of blood. Study;S1-3: samples 1-3; * p< 0,05; ** p< 0,01; *** p< 0,001
